Clearmind Medicine Raises $900K via Discounted Convertible Notes, Amends Conversion Floor to $1.875
CMND sits 59% above its 52-week low of $2.1 on light trading volume (0.1× avg).
Summary
Clearmind Medicine Inc. secured $900,000 in cash by issuing $1,000,000 in discounted convertible promissory notes, further amending the conversion floor price to $1.875 per share.
Key Events · Financing and Capital Events · CMND
-
Amended Conversion Floor Price
The floor price for converting these notes into common shares has been set at $1.875 per share, which is significantly below the current stock price of $3.34.
-
Exceeds Quarterly Limit
The company is exceeding its previously established quarterly limit for issuing such notes, indicating an accelerated need for capital.
-
Significant Dilution Risk
This financing round, following a series of similar transactions, poses substantial dilution risk to existing shareholders due to the discounted issuance and low conversion price relative to the company's market value.
Analysis · CMND · Life Sciences
This transaction represents a substantial capital raise for Clearmind Medicine, equivalent to over 26% of its current market capitalization. The issuance of convertible notes at a 10% discount to principal, coupled with a low conversion floor price of $1.875 (44% below the current stock price), indicates significant dilution risk for existing shareholders. This continues a pattern of highly dilutive financing activities, suggesting ongoing urgent capital needs for the micro-cap company.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $3.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $2.10 to $524.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.